Home>>Peptides>>Urocortin III, mouse

Urocortin III, mouse Sale

目录号 : GC37869

A neuropeptide hormone

Urocortin III, mouse Chemical Structure

Cas No.:357952-10-4

规格 价格 库存 购买数量
1mg 待询 待询
5mg 待询 待询

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF, urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Mouse urocortin III shares 90, 40, 37, and 18% identity to human urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. It is expressed in the hypothalamus, brainstem, lateral septum (LS)/bed nucleus of stria terminalis (BnST) in the CNS and the small intestine, pancreatic β-cells, and skin in the periphery in mice. Urocortin III selectively binds to type 2 CRF receptors (Kis = 5, 1.8, and >100 nM for rat CRF, rat CRF, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF and mouse CRF (EC50s = 0.073 and 0.08 nM, respectively) as well as in cultured anterior pituitary cells expressing endogenous CRF. In vivo, urocortin III (2 μg, i.p.) accelerates metamorphosis of S. hammondii tadpoles.2 Urocortin III (20 μg, i.c.v.) increases exploration in the open field test and decreases latency to enter the lit compartment in the dark-light emergence test in mice, indicating anxiolytic-like activity, and mRNA expression is increased in mouse brain in response to restraint.3 It is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro and in vivo in wild-type mice, however, it is depleted from β-cells in mouse and macaque models of type 2 diabetes, suggesting a role in glycemic control.4

1.Lewis, K., Li, C., Perrin, M.H., et al.Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptorProc. Natl. Acad. Sci. USA98(13)7570-7575(2001) 2.Okada, R., Miller, M.F., Yamamoto, K., et al.Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary glandGen. Comp. Endocrinol.150(3)437-444(2007) 3.Sadhu, C., Dick, K., Tino, W.T., et al.Selective role of PI3Kδ in neutrophil inflammatory responsesBiochem. Biophys. Res. Commun.308(4)764-769(2003) 4.van der Meulen, T., Donaldson, C.J., Cáceres, E., et al.Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretionNat. Med.21(7)769-776(2015)

Chemical Properties

Cas No. 357952-10-4 SDF
分子式 C186H312N52O52S2 分子量 4172.97
溶解度 Soluble in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 0.2396 mL 1.1982 mL 2.3964 mL
5 mM 0.0479 mL 0.2396 mL 0.4793 mL
10 mM 0.024 mL 0.1198 mL 0.2396 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Identification of Urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor

Proc Natl Acad Sci U S A 2001 Jun 19;98(13):7570-5.PMID:11416224DOI:10.1073/pnas.121165198.

The corticotropin-releasing factor (CRF) family of neuropeptides includes the mammalian peptides CRF, urocortin, and urocortin II, as well as piscine urotensin I and frog sauvagine. The mammalian peptides signal through two G protein-coupled receptor types to modulate endocrine, autonomic, and behavioral responses to stress, as well as a range of peripheral (cardiovascular, gastrointestinal, and immune) activities. The three previously known ligands are differentially distributed anatomically and have distinct specificities for the two major receptor types. Here we describe the characterization of an additional CRF-related peptide, Urocortin III, in the human and mouse. In searching the public human genome databases we found a partial expressed sequence tagged (EST) clone with significant sequence identity to mammalian and fish urocortin-related peptides. By using primers based on the human EST sequence, a full-length human clone was isolated from genomic DNA that encodes a protein that includes a predicted putative 38-aa peptide structurally related to other known family members. With a human probe, we then cloned the mouse ortholog from a genomic library. Human and mouse Urocortin III share 90% identity in the 38-aa putative mature peptide. In the peptide coding region, both human and mouse Urocortin III are 76% identical to pufferfish urocortin-related peptide and more distantly related to urocortin II, CRF, and urocortin from other mammalian species. Mouse Urocortin III mRNA expression is found in areas of the brain including the hypothalamus, amygdala, and brainstem, but is not evident in the cerebellum, pituitary, or cerebral cortex; it is also expressed peripherally in small intestine and skin. Urocortin III is selective for type 2 CRF receptors and thus represents another potential endogenous ligand for these receptors.

Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion

Endocrinology 2003 Jul;144(7):3216-24.PMID:12810578DOI:10.1210/en.2002-0087.

Urocortin (Ucn) III, or stresscopin, is a high affinity ligand for the type 2 corticotropin-releasing factor (CRFR2) receptor recently identified in rodents and human. Ucn III was initially identified as a neuropeptide expressed in discrete areas in the brain. In the present study, we demonstrate that Ucn III is expressed in pancreatic beta-cells and in a mouse beta-cell line, MIN6. Ucn III secretion from the cells was measured using a highly specific RIA, and we found that high potassium, forskolin, or high glucose can stimulate Ucn III secretion from these cells. In vivo studies showed that rats receiving an iv Ucn III injection had a significant elevation of plasma glucagon followed by plasma glucose levels compared with rats receiving vehicle. Ucn III injections also result in an increase in plasma insulin levels. The observed effects of Ucn III were blocked by pretreatment with a CRFR2 antagonist, astressin(2)-B. Furthermore, Ucn III stimulated glucagon and insulin release from isolated rat islets, and astressin(2)-B abolished the effects of Ucn III, in keeping with a CRFR2-mediated mechanism. Taken together, the present studies suggest pancreatic Ucn III acting through CRFR2 is involved in the local regulation of glucagon and insulin secretion.

Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and Urocortin III

Peptides 2004 Apr;25(4):659-66.PMID:15165722DOI:10.1016/j.peptides.2004.01.008.

We compared the in vivo efficacy of two selective CRF2 agonists, mouse urocortin II (mUcn II) and human Urocortin III (hUcn III), using food intake, anxious behavior, or ACTH release in CD-1 or Balb/c mice as indices of biological stress responses. All three peptides produced anorexia (Minimal Effective Dose (M.E.D.) for CRF and mUcn II = 0.03 nmol; M.E.D. for hUcn III = 0.3 nmol). Only mUcn II and CRF appeared to increase anxious behaviors in the elevated plus maze test (M.E.D. = 0.3 and 0.01 nmol, respectively). CRF increased the release of plasma ACTH (M.E.D. of 0.3 nmol), while mUcn II and hUcn III had no effect on ACTH release. These data suggest that the CRF2 receptor subtype plays a primary role in the activation of behavioral, but not neuroendocrine, stress responses.

Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours

J Neuroendocrinol 2004 May;16(5):411-22.PMID:15117334DOI:10.1111/j.1365-2826.2004.01170.x.

Following its discovery 20 years ago, corticotropin-releasing hormone (CRH) has been postulated to mediate both hormonal and behavioural responses to stressors. Here, we characterize and describe a behavioural role for the murine gene, UcnIII, which encodes a recently discovered CRH-related neuropeptide, Urocortin III. We found that mouse UcnIII is expressed predominantly in regions of the brain known to be involved in stress-related behaviours, and its expression in the hypothalamus increases following restraint. In addition, we found that intracerebroventricular administration of mUcnIII stimulates behaviours that are associated with reduced anxiety, including exploration of an open field and decreased latency to enter the lit compartment of a dark-light chamber, but has no effect on the elevated-plus maze. Finally, we found that mUcnIII does not exert any effects on the hormonal stress response. Based upon our findings, UcnIII may be an endogenous brain neuropeptide that is modulated by stress and stimulates behaviours associated with reduced anxiety. In this capacity, UcnIII may attenuate stress-related behaviours, which may be useful both to help cope with stressful situations as well as to avoid pathology associated with excessive reaction to stressors.